4 April 2016 - The Department of Health has asked NICE to produce guidance on using mepolizumab in the NHS in England.

The NICE Appraisal Committee has considered the evidence submitted by GSK and the views of non-company consultees and commentators, and clinical experts and patient experts.

The Appraisal Committee will meet again to consider the evidence, this appraisal consultation document and comments from the consultees.

At that meeting, the Committee will also consider comments made by people who are not consultees.

After considering these comments, the Committee will prepare a final appraisal determination (FAD).

The anticipated publication date of the FAD is 1 July 2016.

For more details, go to: https://www.nice.org.uk/guidance/indevelopment/gid-tag519/consultation/html-content

To see the entries for mepolizumab in the MAESTrO database, click here: https://app.maestrodatabase.com/app/reimbursement/browse/technology/mepolizumab